Jasper Therapeutics, Inc. (JSPR) awards 7,500 stock options to director
Rhea-AI Filing Summary
Crutcher Patrick J reported acquisition or exercise transactions in this Form 4 filing.
Jasper Therapeutics, Inc. reported that director Patrick J. Crutcher received a stock option for 7,500 shares of Voting Common Stock on July 31, 2026, exercisable at $0.63 per share. The option vests in full one year after grant, subject to continued service, and expires July 31, 2036, leaving him holding 7,500 options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Crutcher Patrick J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy F1 | 7,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy — 7,500 shares (Direct)
Footnotes (1)
- F1. Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.
Key Figures
Options granted: 7,500 shares
Exercise price: $0.6300 per share
Vesting date: 2027-07-31
+2 more
5 metrics
Options granted
7,500 shares
Stock options for Voting Common Stock granted to Patrick J. Crutcher on 2026-07-31
Exercise price
$0.6300 per share
Exercise price of the granted stock options
Vesting date
2027-07-31
Options vest in full on the first anniversary of the grant date
Expiration date
2036-07-31
Expiration date of the stock option grant
Total derivative holdings after grant
7,500 options
Total stock options held directly by Patrick J. Crutcher after this award
Key Terms
Non-Employee Director Compensation Policy, Stock Option (Right to Buy, Voting Common Stock
3 terms
Non-Employee Director Compensation Policy financial
"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides..."
Stock Option (Right to Buy financial
"security title listed as Stock Option (Right to Buy for this derivative award"
Voting Common Stock financial
"underlying security title identified as Voting Common Stock for the option grant"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stock option grant did Patrick J. Crutcher report at JSPR?
Patrick J. Crutcher reported a grant of stock options for 7,500 shares of Jasper Therapeutics Voting Common Stock. The options were granted on July 31, 2026, giving him the right to buy these shares at a fixed exercise price in the future.
What is the exercise price of Patrick J. Crutcher’s JSPR options?
The granted options carry an exercise price of $0.63 per share. This means Crutcher can purchase up to 7,500 shares of Jasper Therapeutics Voting Common Stock at $0.63 each, regardless of the market price when he chooses to exercise, subject to vesting.
When do Patrick J. Crutcher’s JSPR options vest and expire?
The options vest in full on the first anniversary of the July 31, 2026 grant, subject to his continued service. They have an expiration date of July 31, 2036, after which any unexercised options will lapse and can no longer be used.
How many JSPR options does Patrick J. Crutcher hold after this grant?
Following this transaction, Patrick J. Crutcher directly holds 7,500 stock options related to Jasper Therapeutics Voting Common Stock. The reported total represents his derivative holdings after the grant recorded on July 31, 2026 in this insider report.
Was Patrick J. Crutcher’s JSPR option grant under a Rule 10b5-1 plan?
The available SEC data show the Rule 10b5-1 checkbox is not marked for this report, and no trading plan is referenced in the related footnote. The grant is described instead as automatic under a non-employee director compensation policy.
What policy governs Patrick J. Crutcher’s JSPR option grant?
The grant is described as automatically made under Jasper’s Non-Employee Director Compensation Policy. This policy provides that non-employee directors receive an option to purchase 7,500 shares on the date of each annual meeting of stockholders, with full vesting after one year of continued service.